1545-5017/asset/MPO_centre.gif?v=1&s=8c0b4c386f6ece3ce7f8c5c02144983ee96bc8b6)
Review
Clofarabine in pediatric acute leukemia: Current findings and issues
Article first published online: 21 FEB 2012
DOI: 10.1002/pbc.24112
Copyright © 2012 Wiley Periodicals, Inc.
1545-5017/asset/cover.gif?v=1&s=a75210663ec4a312a5bd8e3022f1967dde569328 "Pediatric Blood & Cancer")
Additional Information
How to Cite
Hijiya, N., Barry, E. and Arceci, R. J. (2012), Clofarabine in pediatric acute leukemia: Current findings and issues. Pediatr. Blood Cancer, 59: 417–422. doi: 10.1002/pbc.24112
Publication History
- Issue published online: 12 JUL 2012
- Article first published online: 21 FEB 2012
- Manuscript Accepted: 30 JAN 2012
- Manuscript Received: 20 DEC 2011
- Abstract
- Article
- References
- Cited By
Keywords:
- ALL;
- clofarabine;
- new agent;
- relapse
Abstract
Clofarabine is a second-generation purine nucleoside analog and has significant anti-leukemic activity as a single agent. It is approved by the United States Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children. Combinations of clofarabine with purine nucleoside analogs or DNA-damaging agents have been investigated utilizing synergistic effects and now tested in a number of studies including a frontline study. In this article, we review the development of clofarabine, rationale and history of combination regimens, and their potential roles and toxicities in the treatment of pediatric ALL that are important to treating clinicians. Pediatr Blood Cancer 2012;59:417–422. © 2012 Wiley Periodicals, Inc.